TransThera Sciences (Nanjing), Inc. (HKG:2617)

Revenue by Segment

Financials in millions CNY. Fiscal year is January - December.

Fiscal Year	FY 2023	FY 2022
Period Ending	Dec 31, 2023	Dec 31, 2022
Development of Innovative Medicines	1.18M	124.00K
Development of Innovative Medicines Growth	852.42%	-
Total	1.18M	124.00K
Total Growth	852.42%	-

Revenue by Geography

Financials in millions CNY. Fiscal year is January - December.

Fiscal Year	FY 2023	FY 2022
Period Ending	Dec 31, 2023	Dec 31, 2022
Mainland China	7.00K	-
Republic of Korea	1.17M	124.00K
Republic of Korea Growth	846.77%	-
Total	1.18M	124.00K
Total Growth	852.42%	-

Data Source: S&P Global Market Intelligence Last updated: Dec 31, 2025

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every six months for this company.

Update frequency:

Semi-annually

Last checked:

Jun 15, 2026

Data Sources Report a data error